Skip to content

Irving Reti

4 papers in the library · 296 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

Genetics of Response to ECT, TMS, Ketamine and Esketamine.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics June 17, 2025 Clio E Franklin, Murat Altinay, Kala Bailey et al. 2 citations

Treatment-resistant mood disorders are often managed with intensive interventions that include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), ketamine, and esketamine, but the role of genetics in clinical response to those interventions is yet to be clearly determined. Here, we review the current literature on the genetics of response to these treatment modalities. To...

Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis.

Psychiatry Research May 1, 2025 Gerard Sanacora, Brian S. Barnett, Bo Hu et al. 2 citations

Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...

Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Network Open June 3, 2024 Manish Kumar Jha, Samuel T. Wilkinson, Kamini Krishnan et al. 29 citations

The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D) trial demonstrated noninferiority of intravenous ketamine vs ECT for nonpsychotic TRD. Clinical features that can guide selection of ketamine vs ECT may inform shared decision-making for patients with TRD. To evaluate whether selected clinical features were associated with...

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

New England Journal of Medicine May 24, 2023 A. Anand, S. Mathew, Gerard Sanacora et al. 263 citations

BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain. METHODS We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression. Patients with...